Pazenir® (paclitaxel formulated as albumin bound nanoparticles) 5 mg/ml powder for dispersion for infusion: temporary supply shortage

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Pazenir
Active substance
paclitaxel
Therapeutic area (MeSH)
Breast Neoplasms
Procedure number
EMEA/H/C/004441
DHPC type
Medicine shortage
Human ATC code
L01CD01
Dissemination date
24/01/2023

How useful was this page?

Add your rating